发布求助
文献互助 智能选刊 最新文献

Lung Cancer Management最新文献

筛选
英文 中文
Current clinical trials and patent update on lung cancer: a retrospective review. 当前肺癌的临床试验和专利更新:回顾性回顾。
IF 2.8
Lung Cancer Management Pub Date : 2021-02-15 DOI: 10.2217/lmt-2020-0029
Harshul Batra, Shrikant Pawar, Dherya Bahl
{"title":"Current clinical trials and patent update on lung cancer: a retrospective review.","authors":"Harshul Batra,&nbsp;Shrikant Pawar,&nbsp;Dherya Bahl","doi":"10.2217/lmt-2020-0029","DOIUrl":"https://doi.org/10.2217/lmt-2020-0029","url":null,"abstract":"<p><p>Several clinical trials using different interventions are currently being sponsored to combat lung cancer at its different stages. The purpose of this study was to provide a portfolio of those trials. All active, open and recruiting clinical trials registered at ClinicalTrials.gov up to March 2018 were included. Information related to 6092 registered lung cancer trials was downloaded. Phase II trials were in the majority, comprising nearly 48.7% of total clinical trials with industry the major sponsor (41.3%) followed by NIH (12.3%). Multicenter studies were the norm accounting for 47.9% and the main study location was the USA (50.9%). Common interventions were radiation (26%), surgery (22%) and EGFR inhibitors (17%). Patent information includes major patent filing office and sponsors. The data analysis provides a comprehensive description of lung cancer trials.</p>","PeriodicalId":43551,"journal":{"name":"Lung Cancer Management","volume":"10 2","pages":"LMT45"},"PeriodicalIF":2.8,"publicationDate":"2021-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/57/30/lmt-10-45.PMC8162165.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39059394","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Simple parameters to solve a complex issue: predicting response to checkpoint inhibitor therapy in lung cancer. 简单的参数解决一个复杂的问题:预测肺癌对检查点抑制剂治疗的反应。
IF 2.8
Lung Cancer Management Pub Date : 2020-11-23 DOI: 10.2217/lmt-2020-0024
James Newman, Isabel Preeshagul, Nina Kohn, Craig Devoe, Nagashree Seetharamu
{"title":"Simple parameters to solve a complex issue: predicting response to checkpoint inhibitor therapy in lung cancer.","authors":"James Newman,&nbsp;Isabel Preeshagul,&nbsp;Nina Kohn,&nbsp;Craig Devoe,&nbsp;Nagashree Seetharamu","doi":"10.2217/lmt-2020-0024","DOIUrl":"https://doi.org/10.2217/lmt-2020-0024","url":null,"abstract":"<p><strong>Background: </strong>Noninvasive biomarkers predicting immune checkpoint inhibitor (ICI) response are urgently needed. We evaluated the predictive value of pretreatment neutrophil-to-lymphocyte ratio (NLR), smoking history, smoking intensity, BMI and programmed death ligand 1 (PD-L1) expression in non-small-cell lung cancer (NSCLC) patients treated with ICIs.</p><p><strong>Materials & methods: </strong>Single-center retrospective study included 137 patients from July 2015 to February 2018. Outcomes included 3-month disease control rate, progression-free survival, and overall survival. Predictive value of biomarkers was assessed independently and in a multivariable model.</p><p><strong>Results: </strong>NLR was associated with all outcomes. Smoking history was predictive of progression-free survival and smoking intensity was predictive of disease control rate. BMI and PD-L1 were not associated with any outcome. High BMI was associated with low NLR.</p><p><strong>Conclusion: </strong>Simple clinical biomarkers can predict response to ICIs. A score incorporating both clinical factors and established tissue/serum biomarkers may be useful in identifying NSCLC patients who would benefit from ICIs.</p>","PeriodicalId":43551,"journal":{"name":"Lung Cancer Management","volume":"10 2","pages":"LMT44"},"PeriodicalIF":2.8,"publicationDate":"2020-11-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/b2/ee/lmt-10-44.PMC8162145.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39059393","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
Efficacy and safety of tyrosine kinase inhibitors in advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutation: a network meta-analysis. 酪氨酸激酶抑制剂治疗表皮生长因子受体突变晚期非小细胞肺癌的疗效和安全性:一项网络荟萃分析。
IF 2.8
Lung Cancer Management Pub Date : 2020-11-23 DOI: 10.2217/lmt-2020-0011
Abdullah Alanazi, Ismaeel Yunusa, Khaled Elenizi, Abdulaziz I Alzarea
{"title":"Efficacy and safety of tyrosine kinase inhibitors in advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutation: a network meta-analysis.","authors":"Abdullah Alanazi,&nbsp;Ismaeel Yunusa,&nbsp;Khaled Elenizi,&nbsp;Abdulaziz I Alzarea","doi":"10.2217/lmt-2020-0011","DOIUrl":"https://doi.org/10.2217/lmt-2020-0011","url":null,"abstract":"<p><strong>Aim: </strong>To compare the efficacy and safety of tyrosine kinase inhibitors (TKIs) as first-line treatment in patients with locally advanced or metastatic non-small-cell lung cancer (NSCLC) with positive <i>EGFR</i> mutation.</p><p><strong>Materials & methods: </strong>Following a systematic literature review until December 2019, we conducted a random-effects pairwise and network meta-analyses (NMA). We ranked treatments for efficacy and safety based on the surface under the cumulative ranking curve (SUCRA).</p><p><strong>Results: </strong>Tyrosine kinase inhibitors of the epidermal growth factor receptor (EGFR-TKI) improved survival outcomes with fewer grade 3 or higher adverse events compared to chemotherapy. Overall survival results suggest that osimertinib has the highest probability of being the most efficacious (SUCRA, 79.9%), followed by dacomitinib (SUCRA, 75.8%). Adverse events results suggest that osimertinib (SUCRA, 84.3%) and gefitinib (SUCRA, 78.9%) has the highest probability of being the safest.</p><p><strong>Conclusion: </strong>In this NMA, we found that osimertinib is the most efficacious and safest EGFR-TKI. These results may guide clinicians in choosing the most appropriate treatment option among EGFR-TKIs for their patient's individual clinical characteristics.</p>","PeriodicalId":43551,"journal":{"name":"Lung Cancer Management","volume":"10 1","pages":"LMT43"},"PeriodicalIF":2.8,"publicationDate":"2020-11-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/lmt-2020-0011","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38709407","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 18
Humanistic burden of living with anaplastic lymphoma kinase-positive non-small-cell lung cancer: findings from the ALKConnect patient insight network and research platform. 间变性淋巴瘤激酶阳性非小细胞肺癌的人文生活负担:来自ALKConnect患者洞察网络和研究平台的研究结果
IF 2.8
Lung Cancer Management Pub Date : 2020-11-20 DOI: 10.2217/lmt-2020-0018
Huamao M Lin, Xiaoyun Pan, Alyssa Biller, Kyla J Covey, Hui Huang, Rebecca Sugarman, Fatima Scipione, Howard West
{"title":"Humanistic burden of living with anaplastic lymphoma kinase-positive non-small-cell lung cancer: findings from the ALKConnect patient insight network and research platform.","authors":"Huamao M Lin,&nbsp;Xiaoyun Pan,&nbsp;Alyssa Biller,&nbsp;Kyla J Covey,&nbsp;Hui Huang,&nbsp;Rebecca Sugarman,&nbsp;Fatima Scipione,&nbsp;Howard West","doi":"10.2217/lmt-2020-0018","DOIUrl":"https://doi.org/10.2217/lmt-2020-0018","url":null,"abstract":"<p><strong>Aim: </strong>Evaluate real-world patient preferences, experiences and outcomes (health-related quality of life [HRQoL]) from patients with anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer (NSCLC) utilizing the ALKConnect Patient Insight Network.</p><p><strong>Patients & methods: </strong>Demographics, disease history/status/treatment, patient preferences and HRQoL (MD Anderson Symptom Inventory lung cancer module, reported as symptom severity and interference) were evaluated for US adults with ALK+ NSCLC.</p><p><strong>Results: </strong>Among 104 patients (median age: 53.0 years, 67.3% female, 40.0% employed), HRQoL and 3-month delay in disease progression were important treatment attributes. Burdensome symptoms included fatigue and disturbed sleep. Symptoms interfered most with work and day-to-day activity. Higher HRQoL was associated with ALK tyrosine kinase inhibitor (TKI) treatment and employment.</p><p><strong>Conclusion: </strong>ALKConnect demonstrated that disease progression, HRQoL, fatigue/sleep, ALK TKIs and employment matter in ALK+ NSCLC.</p>","PeriodicalId":43551,"journal":{"name":"Lung Cancer Management","volume":"10 1","pages":"LMT42"},"PeriodicalIF":2.8,"publicationDate":"2020-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/lmt-2020-0018","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38709406","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Diagnosis and management of small pulmonary atypical carcinoid tumor associated with Cushing syndrome. 与库欣综合征相关的肺部小型非典型类癌的诊断和治疗。
IF 0.9
Lung Cancer Management Pub Date : 2020-09-14 DOI: 10.2217/lmt-2020-0010
Dathe Z Benissan-Messan, Robert E Merritt, Konstantin Shilo, Desmond M D'Souza, Peter J Kneuertz
{"title":"Diagnosis and management of small pulmonary atypical carcinoid tumor associated with Cushing syndrome.","authors":"Dathe Z Benissan-Messan, Robert E Merritt, Konstantin Shilo, Desmond M D'Souza, Peter J Kneuertz","doi":"10.2217/lmt-2020-0010","DOIUrl":"10.2217/lmt-2020-0010","url":null,"abstract":"<p><p>Ectopic adrenocorticotropic hormone (ACTH) syndrome is rare and identification of its source is often challenging. We report the case of an ectopic Cushing syndrome in a young adult male secondary to an occult ACTH producing atypical carcinoid tumor. Extensive biochemical and imaging workup was unrevealing. The diagnosis was aided by Ga-DOTA PET scan demonstrating a suspicious left upper lobe lung nodule. The patient underwent video-assisted thoracoscopic exploration with wedge resection and mediastinal lymphadenectomy of a T2aN2M0 atypical carcinoid, resulting in the normalization of ACTH levels and complete resolution of symptoms. The role of a Ga-DOTA PET scan in diagnosing pulmonary carcinoid tumors and their management are discussed.</p>","PeriodicalId":43551,"journal":{"name":"Lung Cancer Management","volume":"9 4","pages":"LMT41"},"PeriodicalIF":0.9,"publicationDate":"2020-09-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/3b/86/lmt-09-41.PMC7729590.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38709411","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Biopsy frequency and complications among lung cancer patients in the United States. 美国肺癌患者的活检频率和并发症
IF 2.8
Lung Cancer Management Pub Date : 2020-08-17 DOI: 10.2217/lmt-2020-0022
Yichen Zhang, Lizheng Shi, Michael J Simoff, Oliver J Wagner, James Lavin
{"title":"Biopsy frequency and complications among lung cancer patients in the United States.","authors":"Yichen Zhang, Lizheng Shi, Michael J Simoff, Oliver J Wagner, James Lavin","doi":"10.2217/lmt-2020-0022","DOIUrl":"10.2217/lmt-2020-0022","url":null,"abstract":"<p><strong>Objective: </strong>This study aimed to describe the frequency and distribution of biopsy procedures for patients diagnosed and treated for primary lung cancer.</p><p><strong>Study design: </strong>Retrospective cohort study within an administrative database.</p><p><strong>Materials & methods: </strong>This observational study used data from the IBM MarketScan<sup>®</sup> Databases between 2013 and 2015.</p><p><strong>Results: </strong>The total number of lung biopsies performed among eligible subjects was 32,814; an average of 1.7 biopsies per patient. Bronchoscopy and percutaneous approaches accounted for 95% of all procedures. Complication rates by procedure are remarkably similar irrespective of biopsy frequency.</p><p><strong>Conclusion: </strong>Nearly half (46%) of patients in this population experienced multiple biopsies prior to diagnosis. Further, biopsy choice or sequence in patients receiving multiple procedures was unpredictable.</p>","PeriodicalId":43551,"journal":{"name":"Lung Cancer Management","volume":"9 4","pages":"LMT40"},"PeriodicalIF":2.8,"publicationDate":"2020-08-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/77/e8/lmt-09-40.PMC7729592.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38709410","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 16
The role of palliative care in the management of patients with lung cancer. 姑息治疗在肺癌患者管理中的作用。
IF 2.8
Lung Cancer Management Pub Date : 2020-07-29 DOI: 10.2217/lmt-2020-0016
Irena Tan, Kavitha Ramchandran
{"title":"The role of palliative care in the management of patients with lung cancer.","authors":"Irena Tan,&nbsp;Kavitha Ramchandran","doi":"10.2217/lmt-2020-0016","DOIUrl":"https://doi.org/10.2217/lmt-2020-0016","url":null,"abstract":"<p><p>Palliative care (PC) is the care of patients and their families with serious illness and is rapidly becoming an important part of the care of cancer patients. Patients with advanced lung cancer are a highly symptomatic population of patients and clearly experience benefits in quality of life and potentially benefits in overall survival when PC is incorporated early on after diagnosis. However, referrals to PC are still reliant on clinical judgment of patient prognosis and symptom burden. Moving forward, improving the integration of PC and lung cancer care will require more efficient real-time screening of patient symptoms, which may be accomplished through the use of patient-reported outcomes.</p>","PeriodicalId":43551,"journal":{"name":"Lung Cancer Management","volume":"9 4","pages":"LMT39"},"PeriodicalIF":2.8,"publicationDate":"2020-07-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/lmt-2020-0016","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38709409","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Choosing the best first-line therapy: NSCLC with no actionable oncogenic driver. 选择最佳一线治疗:无可操作的致癌驱动因素的非小细胞肺癌。
IF 2.8
Lung Cancer Management Pub Date : 2020-07-24 DOI: 10.2217/lmt-2020-0003
So Yeon Kim, Balazs Halmos
{"title":"Choosing the best first-line therapy: NSCLC with no actionable oncogenic driver.","authors":"So Yeon Kim,&nbsp;Balazs Halmos","doi":"10.2217/lmt-2020-0003","DOIUrl":"https://doi.org/10.2217/lmt-2020-0003","url":null,"abstract":"<p><p>Combination platinum-based therapy has been the standard of care for the treatment of advanced non-small-cell lung cancer (NSCLC). Immunotherapy has emerged and demonstrated to show benefit in the treatment of patients with advanced NSCLC. In this review, we discuss the pivotal trials that led to the US FDA approval of specific immunotherapy regimens in particular patient populations. We discuss the optimal use of immunotherapy as monotherapy based on the KEYNOTE-024, KEYNOTE-042 and IMpower110 trials, chemo-immunotherapy based on KEYNOTE-189, KEYNOTE-407, IMpower150 and IMpower130 trials, and as doublet immunotherapy based on CheckMate-227. We also discuss the role and limitations of PD-L1 expression and tumor mutational burden as predictive biomarkers in response to single-agent immunotherapy and combination chemoimmunotherapy. Furthermore, we discuss emerging resistance markers such as <i>STK11</i> and <i>KEAP1</i> mutations in immunotherapy response and briefly discuss the role of immunotherapy in elderly patients and in patients with actionable mutations.</p>","PeriodicalId":43551,"journal":{"name":"Lung Cancer Management","volume":"9 3","pages":"LMT36"},"PeriodicalIF":2.8,"publicationDate":"2020-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/lmt-2020-0003","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38245942","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 13
Computed tomography texture analysis of response to second-line nivolumab in metastatic non-small cell lung cancer. 转移性非小细胞肺癌对二线纳武单抗反应的计算机断层扫描结构分析。
IF 2.8
Lung Cancer Management Pub Date : 2020-07-22 DOI: 10.2217/lmt-2020-0002
Rahul Ladwa, Kate E Roberts, Connor O'Leary, Nicole Maggacis, Kenneth J O'Byrne, Kenneth Miles
{"title":"Computed tomography texture analysis of response to second-line nivolumab in metastatic non-small cell lung cancer.","authors":"Rahul Ladwa,&nbsp;Kate E Roberts,&nbsp;Connor O'Leary,&nbsp;Nicole Maggacis,&nbsp;Kenneth J O'Byrne,&nbsp;Kenneth Miles","doi":"10.2217/lmt-2020-0002","DOIUrl":"https://doi.org/10.2217/lmt-2020-0002","url":null,"abstract":"<p><strong>Objectives: </strong>Assess computed tomography texture analysis of patients likely to benefit from nivolumab.</p><p><strong>Materials & methods: </strong>Texture analysis was used to quantify heterogeneity within the largest tumor before immunotherapy. Histogram analysis was classified as hyperdense (positive skewness) or hypodense (negative skewness) and subclassified on median standard deviation value or entropy measurement.</p><p><strong>Results: </strong>47 patients were included. At a median follow-up of 18 months, statistical significant differences in progression-free survival were observed when stratified by positive skewness with low entropy, hazard ratio: 0.43 (0.19-0.95); p = 0.036, and positive skewness with low standard deviation, hazard ratio: 0.42 (0.18-0.96); p = 0.04.</p><p><strong>Conclusion: </strong>Patients who derive a clinical benefit to Nivolumab show a computed tomography texture of a hyperdense yet homogenous tumor.</p>","PeriodicalId":43551,"journal":{"name":"Lung Cancer Management","volume":"9 3","pages":"LMT38"},"PeriodicalIF":2.8,"publicationDate":"2020-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/lmt-2020-0002","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38246384","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 8
Prognostic significance of the neutrophil/lymphocyte ratio in patients undergoing treatment with nivolumab for recurrent non-small-cell lung cancer. 中性粒细胞/淋巴细胞比值在接受纳武单抗治疗复发性非小细胞肺癌患者中的预后意义
IF 2.8
Lung Cancer Management Pub Date : 2020-07-20 DOI: 10.2217/lmt-2020-0014
Bernardo L Rapoport, Annette J Theron, Daniel A Vorobiof, Lizanne Langenhoven, Jacqueline M Hall, Ronwyn I Van Eeden, Teresa Smit, Sze-Wai Chan, Michael C Botha, Johann I Raats, Margriet De Necker, Ronald Anderson
{"title":"Prognostic significance of the neutrophil/lymphocyte ratio in patients undergoing treatment with nivolumab for recurrent non-small-cell lung cancer.","authors":"Bernardo L Rapoport,&nbsp;Annette J Theron,&nbsp;Daniel A Vorobiof,&nbsp;Lizanne Langenhoven,&nbsp;Jacqueline M Hall,&nbsp;Ronwyn I Van Eeden,&nbsp;Teresa Smit,&nbsp;Sze-Wai Chan,&nbsp;Michael C Botha,&nbsp;Johann I Raats,&nbsp;Margriet De Necker,&nbsp;Ronald Anderson","doi":"10.2217/lmt-2020-0014","DOIUrl":"https://doi.org/10.2217/lmt-2020-0014","url":null,"abstract":"<p><strong>Aim: </strong>We investigated the prognostic potential of pretherapy measurement of the neutrophil/lymphocyte ratio (NLR) in patients (n = 56) with non-small-cell lung cancer deemed suitable for treatment with nivolumab.</p><p><strong>Materials & methods: </strong>This was a multicenter, noninterventional, retrospective data analysis, involving five oncology centers.</p><p><strong>Results: </strong>Patients with prenivolumab NLR values of <5 and ≥5 had respective median overall survival (OS) values of 14.5 and 7.02 months (p = 0.0026). Patients with ≤2 and >2 metastatic sites had median OS values of 11.4 and 6.1 months, respectively (p = 0.0174). A Cox multiple regression model revealed baseline NLR ≥5 as the only variable significantly associated with decreased OS (p < 0.0447).</p><p><strong>Conclusion: </strong>Pretreatment elevated NLR values are associated with poor outcomes in patients with recurrent metastatic non-small-cell lung cancer treated with nivolumab.</p>","PeriodicalId":43551,"journal":{"name":"Lung Cancer Management","volume":"9 3","pages":"LMT37"},"PeriodicalIF":2.8,"publicationDate":"2020-07-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/lmt-2020-0014","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38245943","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 4
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信